CSL Limited Stock

Equities

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. 02:11:03 2024-06-07 am EDT 5-day change 1st Jan Change
289 AUD -0.17% Intraday chart for CSL Limited +3.18% +0.82%
Sales 2024 * 14.72B 22.36B Sales 2025 * 15.93B 24.21B Capitalization 91.94B 140B
Net income 2024 * 2.71B 4.12B Net income 2025 * 3.26B 4.95B EV / Sales 2024 * 6.91 x
Net Debt 2024 * 9.82B 14.91B Net Debt 2025 * 8.65B 13.14B EV / Sales 2025 * 6.31 x
P/E ratio 2024 *
33.7 x
P/E ratio 2025 *
28 x
Employees 32,065
Yield 2024 *
1.39%
Yield 2025 *
1.62%
Free-Float 99.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.17%
1 week+3.18%
Current month+3.18%
1 month+3.25%
3 months+1.24%
6 months+8.27%
Current year+0.82%
More quotes
1 week
279.40
Extreme 279.4
290.59
1 month
275.04
Extreme 275.04
290.59
Current year
265.14
Extreme 265.14
306.42
1 year
228.65
Extreme 228.65
309.69
3 years
228.65
Extreme 228.65
319.78
5 years
206.01
Extreme 206.01
342.75
10 years
63.77
Extreme 63.77
342.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-05-31
Director of Finance/CFO 59 20-09-30
Chief Tech/Sci/R&D Officer 62 20-09-30
Members of the board TitleAgeSince
Director/Board Member 69 19-12-08
President 68 90-06-30
Director/Board Member 61 21-08-18
More insiders
Date Price Change Volume
24-06-07 289 -0.17% 494,656
24-06-06 289.5 +1.27% 648,360
24-06-05 285.9 +1.37% 927,555
24-06-04 282 +0.23% 579,240
24-06-03 281.3 +0.44% 546,335

Delayed Quote Australian S.E., June 07, 2024 at 02:11 am EDT

More quotes
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
190.3 USD
Average target price
202.7 USD
Spread / Average Target
+6.53%
Consensus